

# Pitt BioForge Announces Successful Completion of Advanced Manufacturing of Microarray Patches with Panther Life Sciences

*Pitt BioForge and Panther Life Sciences achieve one of the most difficult problems in microarray patch (MAP) manufacturing: at-scale, low cost MAPs.*

PITTSBURGH, PA, UNITED STATES, December 8, 2025 /EINPresswire.com/ -- [Pitt BioForge](#) and [Panther Life Sciences](#) announced the successful completion of BioForge's first manufacturing project, achieving what had long been considered one of the most difficult problems in microarray patch (MAP) manufacturing: establishing at-scale, low cost MAPs.



This expansion solidifies Panther's Pittsburgh base as a hub for next-generation process and discrete manufacturing, anchored by the discoveries and discipline developed through its BioForge collaboration.

BioForge brings together external collaborators to pursue shared, measurable goals within a fixed budget and timeline. Each project leverages resources and personnel from both BioForge and its partners, with work conducted at BioForge's facilities.

After a rigorous selection process, Panther Life Sciences was accepted as a BioForge project. Over the course of a year of close collaboration, the two organizations tackled fundamental manufacturing challenges that have historically limited the commercial viability of MAP technologies.

"Our partnership with BioForge demonstrated that large-volume MAP manufacturing is now achievable and economically feasible," said Carlos Bhola, CEO of Panther Life Sciences. "Through our collaboration, we solved critical process challenges that significantly reduced production costs, demonstrated high volume manufacturing, and established the foundation for scaling the next-generation of treatments. As a result of our successful partnership with BioForge, Panther is establishing a manufacturing competency center in Pittsburgh for a wide range of treatments, where we will continue to advance our core manufacturing processes and discrete manufacturing capabilities."



We solved critical process challenges that significantly reduced production costs, demonstrated high volume manufacturing, and established the foundation for scaling the next-generation of treatments.”

*Carlos Bhola, CEO of Panther Life Sciences*

With this success, Panther now has the ability to manufacture MAPs at scale, enabling deployment across a comprehensive pipeline of treatments, from skin health to systemic treatments. Panther’s platform produces direct-to-consumer, self-applied treatments that are shelf-stable, minimally invasive, and patient-centric, making them especially suited to address untreated and undertreated people globally.

“We count this as a hybrid success: it’s both a startup and a licensing opportunity,” said Kaigham Gabriel, CEO of BioForge. Panther is an innovative healthcare company that is hiring high caliber talent and expanding its presence in

Pittsburgh.”

Following the BioForge project, Panther is expanding its Pittsburgh operations, adding discrete manufacturing capabilities and establishing a competency center to further extend its process innovation capabilities. This expansion solidifies Panther’s Pittsburgh base as a hub for next-generation process and discrete manufacturing, anchored by the discoveries and discipline developed through its BioForge collaboration.

#### About Panther Life Sciences

Panther is unlocking the tremendous biological powers of our skin, delivering highly efficacious shelf-stable treatments by mail that previously would have required refrigeration and trained healthcare providers. Panther’s precisely-engineered microarray patches (MAPs) address skin health (skincare, medical aesthetics) and treat systemic ailments along the immunological spectrum (infectious diseases, cancer, allergies, autoimmune diseases, etc.).

Panther’s MAPs enable automated data integration with provider and public health systems, and its AI-based predictive analytics enable rapid treatment development, improved patient care and enhanced disease management. Via advanced GMP manufacturing, direct-to-consumer distribution and self-application, Panther’s MAPs are affordable, simultaneously enabling commercial success and universal access.

#### About BioForge

BioForge’s mission is to accelerate innovations and breakthroughs in the manufacturing of precision medicines to speed their delivery, use, and impact. Based in Pittsburgh, PA, the BioForge project teams work to demonstrate scaling and delivery of precision medicines in less time, more efficiently and cost-effectively enabling equitable access to these life-changing medicines for all.

AM Public Relations

Panther Life Sciences Corporation  
panther@ampublicrelations.coms

---

This press release can be viewed online at: <https://www.einpresswire.com/article/872932361>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.